These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

47 related articles for article (PubMed ID: 9734367)

  • 1. PPAR--the good news and the bad.
    Nat Med; 1998 Sep; 4(9):981. PubMed ID: 9734367
    [No Abstract]   [Full Text] [Related]  

  • 2. PPARgamma and colorectal carcinoma: conflicts in a nuclear family.
    Seed B
    Nat Med; 1998 Sep; 4(9):1004-5. PubMed ID: 9734386
    [No Abstract]   [Full Text] [Related]  

  • 3. Activators of the nuclear receptor PPARgamma enhance colon polyp formation.
    Saez E; Tontonoz P; Nelson MC; Alvarez JG; Ming UT; Baird SM; Thomazy VA; Evans RM
    Nat Med; 1998 Sep; 4(9):1058-61. PubMed ID: 9734400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Warner-Lambert voluntarily withdraws Rezulin.
    Diabetes Technol Ther; 2000; 2(2):290. PubMed ID: 11469273
    [No Abstract]   [Full Text] [Related]  

  • 5. Diabetes drug Rezulin: take it, but take precautions.
    Health News; 1999 May; 5(6):7. PubMed ID: 10546576
    [No Abstract]   [Full Text] [Related]  

  • 6. [PPAR gamma and thiozolidinedione derivatives as an antidiabetic drug for treating insuline resistance].
    Horikoshi H; Yachi M
    Tanpakushitsu Kakusan Koso; 2000 Apr; 45(6 Suppl):1096-101. PubMed ID: 10771679
    [No Abstract]   [Full Text] [Related]  

  • 7. The chase is on (and I'm mad as hell).
    Ponte CD
    J Am Pharm Assoc (Wash); 2000; 40(4):466. PubMed ID: 10932454
    [No Abstract]   [Full Text] [Related]  

  • 8. Rezulin (troglitazone) greatly increases cyclosporine metabolism.
    Frantz RP; Nguyen TT
    J Heart Lung Transplant; 1998 Oct; 17(10):1037-8. PubMed ID: 9811416
    [No Abstract]   [Full Text] [Related]  

  • 9. Avandia, a leading alternative for Rezulin patients, prescribed to more than 700,000 patients.
    Diabetes Technol Ther; 2000; 2(2):292. PubMed ID: 11469275
    [No Abstract]   [Full Text] [Related]  

  • 10. Actos (pioglitazone HCL) provides a safe, effective alternative for patients formerly taking Rezulin.
    Diabetes Technol Ther; 2000; 2(2):290-1. PubMed ID: 11469274
    [No Abstract]   [Full Text] [Related]  

  • 11. [Oral therapy in type 2 diabetes. Critical evaluation of glitazones].
    Lotz N
    MMW Fortschr Med; 2002 Jan; 144(3-4):48-50. PubMed ID: 11862793
    [No Abstract]   [Full Text] [Related]  

  • 12. Plaintiff's attorney actively seeking out patients who have used various FDA approved medications and who "may be entitled to compensation for damages caused by these medications".
    South D
    J Miss State Med Assoc; 2000 Nov; 41(11):798-9. PubMed ID: 11107716
    [No Abstract]   [Full Text] [Related]  

  • 13. Rezulin pulled in the UK.
    Zurlinden J
    Nurs Spectr (Wash D C); 1998 May; 8(9):25. PubMed ID: 10542729
    [No Abstract]   [Full Text] [Related]  

  • 14. Diabetes recall. Though Rezulin's withdrawal is a blow for some patients, there are ways to cope. Here's how.
    Gorman C
    Time; 2000 Apr; 155(13):94. PubMed ID: 11009709
    [No Abstract]   [Full Text] [Related]  

  • 15. New labeling and use changes for Rezulin.
    Klonoff DC
    Diabetes Technol Ther; 1999; 1(3):350. PubMed ID: 11484719
    [No Abstract]   [Full Text] [Related]  

  • 16. Rezulin to be withdrawn from the market.
    Diabetes Technol Ther; 2000; 2(2):289. PubMed ID: 11469272
    [No Abstract]   [Full Text] [Related]  

  • 17. NIH opens conflict-of-interest investigation.
    Cimons M
    Nat Med; 1999 Feb; 5(2):129-30. PubMed ID: 9930847
    [No Abstract]   [Full Text] [Related]  

  • 18. Company played down drug's risks, report says.
    Gottlieb S
    BMJ; 2001 Mar; 322(7288):696. PubMed ID: 11264205
    [No Abstract]   [Full Text] [Related]  

  • 19. From the Food and Drug Administration.
    Nightingale SL
    JAMA; 1997 Dec; 278(21):1728. PubMed ID: 9388135
    [No Abstract]   [Full Text] [Related]  

  • 20. [Perspective for development of insulin sensitizers].
    Kadowaki T
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():566-72. PubMed ID: 12387052
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.